ClinicalTrials.gg
CompletedNCT04332172e-HealthUpdated Oct 14, 2026Results posted

Scaling Up: A Multi-Site Trial of e-SBI for Alcohol Use in Pregnancy

An interventional study of General information and Baseline brief intervention in Fetal Alcohol Spectrum Disorders, Fetal Alcohol Syndrome and Fetal Alcohol Effect, sponsored by Michigan State University. Completed at 1 site in United States. Open to female participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Michigan State University · Not applicable, Interventional, and Prevention

How we know

Updated Oct 14, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
384
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies in Fetal Alcohol Spectrum Disorders with a site in United States — 10 open to participants now, 11 under way, none of them phase 3. Fetal Alcohol Spectrum Disorders · United States.

Enrollment
5th of 34
384 · median 85
Started
2023
with 3 others
No phase
22 of 37
9 open now
Registered
22nd of 37
by date
Lead sponsor
1 of 37
Michigan State University

Among the 37 studies in Fetal Alcohol Spectrum Disorders with a site in United States, this one is the 5th largest by enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2023, is one of 22 with no phase, and was the 22nd registered.

Fetal Alcohol Spectrum Disorders

65 studies on the registry are indexed under Fetal Alcohol Spectrum Disorders; 13 are open to participants now.

Browse Fetal Alcohol Spectrum Disorders studies →

Open to participants now

10 of the 37 studies in Fetal Alcohol Spectrum Disorders with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Fetal Alcohol Spectrum Disorders studies recruiting now, 4 (33%) set no upper age limit and 8 (67%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 35 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Fetal Alcohol Spectrum Disorders with a site in United States, or all of them as a file.
02

Study summary

The purpose of this research study is to find out if pregnant women screening positive for alcohol risk like the brief alcohol intervention application that the investigators have developed (called the MommyCheckup, which is a technology-delivered SBIRT, or e-SBIRT), and if it helps them to reduce alcohol use. The investigators also wish to test whether e-SBIRT effects can be enhanced by booster sessions and/or tailored text messages.

Read the detailed description

This factorial trial will include 384 participants. Participants will be pregnant women age 18-35 years who score positive on a frequently used and well-validated screening tool for alcohol use risk in pregnancy (the T-ACE). We will also add an additional requirement of either drinking weekly or more in the past month, or having 4 or more drinks at a time at least monthly in the 12 months before becoming pregnant. To be eligible for the study, participants must also report smartphone ownership, willingness to receive study-related text messages and to use their smartphone for study-related assessments and/or booster sessions, and being at 20 weeks gestation or less. Participants will be excluded if they are not planning to carry the pregnancy to term, or are unable to communicate in English. All participants must reside in Connecticut, Massachusetts, or Michigan. Completion of the baseline assessment is also necessary for inclusion.

Participants will be recruited via community flyers as well as by online posts, flyers, and other advertising via multiple digital platforms that may appear as banners, text, images, video, and/or URL links to the study website, which further links to the screening survey.. The flyers and ads will contain basic information indicating that they are for a health-related study for women 18-35 years of age who can communicate in English. Interested women meeting these criteria will be provided a website address, QR code, or link to a study website, where they will be presented with an electronic information sheet, which they may access via their own smartphone or tablet. Those who click "I agree" at the end of this information sheet, will be invited to complete the initial computer-directed screening survey via a link from the study website to a Qualtrics survey. This survey will ask a range of questions so that the study's inclusion and exclusion criteria are not readily apparent (in order to limit fraud).

The screening survey will be used to determine whether initial inclusion criteria have been met [(age, state of residence, pregnancy status, and alcohol risk (T-ACE positive and either drinking weekly or more in the past month, or having 4 or more drinks at a time at least monthly in the 12 months before becoming pregnant)]. Study staff will contact interested women who meet study inclusion criteria by phone in order to validate their eligibility (survey completed by a real person, who can communicate in English, has a working smartphone, is able to receive text messages, and understands study requirements). The following strategies will be implemented to reduce the possibility of fraudulent participation: 1) manual review of IP addresses to screen for duplicates and identify addresses of non-US origin, detect fraudulent completion (e.g., bots), 2) manual review of Qualtrics survey data to detect suspicious response times (e.g., completing the survey too quickly), unusual patterns in responses, respondent names, respondent email addresses, and patterned completion timestamps indicating that one person/bot is completing the survey repeatedly until eligible, 3) inclusion of a required open-ended narrative response to detect fraudulent completion, and 4) inclusion of invisible questions that only a bot could respond to, as well as visible nonsense questions directing the respondent to provide a particular answer. Only interested women who pass these screens and can be confirmed via the phone call will be enrolled.

The full trial consent will also be presented electronically and will proceed only if participants provide written informed consent via e-signature (using DocuSign, see section 10.1.3 of the protocol for additional information). Participants who meet all eligibility criteria and who provide consent will then be randomly assigned to a study condition during the baseline assessment. The staff member who enrolls the participant will not have access to the assigned condition/content at the time of consent and initial study condition assignment.

This trial includes varying levels of two separate interventions. The interactive and tailored baseline MommyCheckup single-session e-SBIRT was built on principles of Motivational Interviewing and Self-Determination Theory, and is presented to participants directly via their own electronic device (e.g., smartphone, tablet), which interacts with them through an animated talking narrator. The e-SBIRT booster sessions will be sent to participants as a text message that includes a link to the booster content. Participants will be texted these links on two occasions: 6 weeks following the baseline session, and at 30 weeks gestation. Participants assigned to the text messaging intervention will receive a test message at the conclusion of their baseline session, in order to confirm that the software has the correct cellphone number. These participants will then begin receiving text messages twice weekly until after the 34-week assessment, or until they text back "STOP" to end the messages.

Following the baseline session, participants will be asked to complete follow-up assessments at 4 weeks post-baseline, at 27 weeks gestation, 34 weeks gestation, and at 4 weeks postpartum. In addition, all participants will be mailed a nail specimen collection kit at 36 weeks gestation asking them to provide nail clippings that will be analyzed for Ethyl Glucuronide (EtG). Fingernails will be collected at 36 weeks gestation. Toenails may be collected at 38 weeks gestation as an alternative to fingernails. Nail types may not be mixed for a single specimen collection. Specimens from all available fingernails or toenails weighing 50-100 mg gathered at 36 weeks (fingernails) or 38 weeks (toenails) will allow for sufficient nail growth to capture EtG as evidence of alcohol use concentrated in the timeframe of approximately 20-34 weeks gestation, based on typical fingernail and toenail growth rates. Additionally, this timeframe will allow us to avoid detecting post-delivery alcohol use since it takes approximately two weeks for fingernails and four weeks for toenails to grow sufficiently for detectability. Participants will be reminded of the upcoming nail specimen collection at their 27-week and 34-week data collections, plus reminders will be included when the survey links are sent by text for these data collection timepoints. In the event of preterm birth, nail specimens will be requested immediately. The level of detectability for either nail type will be set at 8 pg/mg, which is the lower level of quantitation used for research (the standard level of detectability used for non-research testing is 20 pg/mg). (NOTE: Biospecimen (nails) collection was discontinued as of 9/30/2025 and specimens were not analyzed after the first 59 samples.)

03

Conditions studied

  • Fetal Alcohol Spectrum Disorders
  • Fetal Alcohol Syndrome
  • Fetal Alcohol Effect
04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-35 years
  • Pregnant
  • Self-report of alcohol risk (those who score positive on the T-ACE screen (Sokol, Martier, \& Ager, 1989), and also report either drinking weekly or more in the past month, or having 4 or more drinks at a time at least monthly in the 12 months before becoming pregnant
  • 20 weeks or less gestation
  • Planning to give birth in either Connecticut, Massachusetts, or Michigan
  • Owning a mobile device that they are willing to use to receive study-related text reminders and to complete online study activities including assessments/boosters
  • Completion of baseline assessment (enrollment criterion)

Exclusion criteria

Exclusion Criteria:

  • Not planning to carry the baby to term
  • Unable to communicate in English
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Single (Outcomes assessor)
Enrollment
384 participants (actual)

Study arms

  • Placebo comparator
    General information

    Control, which includes treatment as usual plus referral resources

    Other: General information

  • Experimental
    General information + SMS

    SMS refers to tailored text messaging.

    Other: General information · Behavioral: SMS

  • Experimental
    Baseline brief intervention

    Brief technology-delivered intervention for alcohol use during pregnancy

    Behavioral: Baseline brief intervention

  • Experimental
    Baseline brief intervention + SMS

    Brief technology-delivered intervention for alcohol use during pregnancy, plus tailored text messaging

    Behavioral: Baseline brief intervention · Behavioral: SMS

  • Experimental
    Baseline brief intervention + 2 booster sessions

    Brief technology-delivered intervention for alcohol use during pregnancy, plus two very brief (\<5 minutes) online boosters using the participants' own mobile device.

    Behavioral: Baseline brief intervention · Behavioral: Remote online booster sessions

  • Experimental
    Baseline brief intervention + 2 booster sessions + SMS

    Brief technology-delivered intervention for alcohol use during pregnancy, plus two very brief (\<5 minutes) online boosters using the participants' own mobile device, plus tailored SMS.

    Behavioral: Baseline brief intervention · Behavioral: Remote online booster sessions · Behavioral: SMS

Interventions

  • OtherGeneral information

    General information related to pregnancy is provided electronically.

  • BehavioralBaseline brief intervention

    Interactive brief motivational intervention is delivered electronically. Provides an introduction, describing the purpose and duration, emphasizing the non-judgmental nature of the brief intervention (BI). Uses a high-quality video featuring gain-framed messaging, quit recommendation, and testimonial from a race-matched woman; tailored on race-ethnicity, efficacy, binge frequency, and level of concern regarding her own alcohol use. The e-BI poses a question regarding the participant's willingness to avoid alcohol throughout her pregnancy. Responses to this question will sort participants into one of three major branches, each using motivational principles to promote alcohol abstinence during pregnancy.

  • BehavioralRemote online booster sessions

    Two \< 5-minute online e-BI boosters will be sent to participants via text link (one at 6 weeks post-baseline and one at 30 weeks gestation). The boosters will include a brief summary of the prior session in terms of the participant's concerns and goals. It will also include an assessment of her current status regarding (a) use of alcohol, and (b) intentions regarding future use of alcohol. A brief (1-2 minute) video tailored on her current status and prior goal will be provided. Finally, the boosters will contain optional goal-setting regarding reaching or maintaining abstinence.

  • BehavioralSMS

    Tailored text messages (SMS) will be sent to participants twice a week from baseline throughout her pregnancy (or until she opts out). The messages will be tailored on her quit status, goals, efficacy, level of concern, gestation, and perceived advantages of change. Messages will follow current state of the art regarding messaging preferences, tailoring, and gain-framing. The current list includes messages regarding fetal development, nutrition, exercise, and stress management, as well as alcohol.

06

What researchers measure

Primary outcomes

  1. Number of Participants Abstinent From Alcohol as Measured by Timeline FollowBack Calendar Recall

    The primary outcome of abstinence will be defined as no self-report of alcohol use in the past 90 days via Timeline FollowBack, measured at 34 weeks gestation.

    Time frame: 90 days prior to 34 weeks gestation

Secondary outcomes

  1. Number of Participants With a Healthy Birth Outcome (Full-term Live Birth of Normal Birthweight, With no Days in NICU)

    Healthy birth outcome, using birth outcome data from the state of birth, is defined as a full-term live birth (\>=36 weeks + 6 days) of normal birthweight (\>2500 gms) and with no days in neonatal intensive care.

    Time frame: Measured at birth, which was up to 42 weeks gestation

07

Results

Posted Oct 14, 2026
Limitations and caveats
* Alcohol abstinence was based on self-report, making this outcome subject to social desirability bias. * Participants were recruited via social media, potentially introducing a selection bias toward individuals more likely to engage with digital health tools.

Participant flow

Participants were recruited between May 2023 and October 2024 from throughout the United States via ads placed on social media (Facebook and Instagram) and flyers distributed at prenatal care clinics in Michigan and Massachusetts.

Baseline Intervention
Participant flow — Baseline Intervention
MilestoneGeneral InformationGeneral Information + SMSBaseline Brief InterventionBaseline Brief Intervention + SMSBaseline Brief Intervention + 2 Booster SessionsBaseline Brief Intervention + 2 Booster Sessions + SMS
Started636663666363
Completed636663666363
Not completed000000
Pregnancy Intervention
Participant flow — Pregnancy Intervention
MilestoneGeneral InformationGeneral Information + SMSBaseline Brief InterventionBaseline Brief Intervention + SMSBaseline Brief Intervention + 2 Booster SessionsBaseline Brief Intervention + 2 Booster Sessions + SMS
Started636663666363
Completed626462655961
Not completed121142
Withdrew: Pregnancy loss121121
Withdrew: Withdrawal by subject000021

Outcome measures

PrimaryNumber of Participants Abstinent From Alcohol as Measured by Timeline FollowBack Calendar Recall

The primary outcome of abstinence will be defined as no self-report of alcohol use in the past 90 days via Timeline FollowBack, measured at 34 weeks gestation.

Time frame:
90 days prior to 34 weeks gestation
Reported as:
Count of participants · Participants
Number of Participants Abstinent From Alcohol as Measured by Timeline FollowBack Calendar Recall
ParticipantsGeneral InformationGeneral Information + SMSBaseline Brief InterventionBaseline Brief Intervention + SMSBaseline Brief Intervention + 2 Booster SessionsBaseline Brief Intervention + 2 Booster Sessions + SMS
Number of Participants Abstinent From Alcohol as Measured by Timeline FollowBack Calendar Recall424749464453
Statistical analysis
  • General Information vs Baseline Brief Intervention + 2 Booster Sessions + SMS · Regression, Logistic · p = 0.0109 (significance threshold: p\<0.05) · Odds ratio (or): 0.284 · 95% CI 0.108 to 0.748general information vs. BI + 2 boosters + text messaging
  • Baseline Brief Intervention + SMS vs Baseline Brief Intervention + 2 Booster Sessions + SMS · Regression, Logistic · p = 0.059 (significance threshold: p\<0.05) · Odds ratio (or): 2.830 · 95% CI 1.066 to 7.511BI + boosters + text messaging versus BI +text messaging
  • General Information vs Baseline Brief Intervention · Regression, Logistic · p = 0.0849 (significance threshold: p\<0.05) · Odds ratio (or): 0.462 · 95% CI 0.192 to 1.112general information vs BI
  • General Information vs General Information + SMS · Regression, Logistic · p = 0.1471 (significance threshold: p\<0.05) · Odds ratio (or): 1.873 · 95% CI 0.802 to 4.374text messaging vs. general information
  • General Information + SMS vs Baseline Brief Intervention + 2 Booster Sessions + SMS · Regression, Logistic · p = 0.2275 (significance threshold: p\<0.05) · Odds ratio (or): 0.533 · 95% CI 0.192 to 1.482text messaging vs. BI + 2 boosters + text messaging
  • General Information + SMS vs Baseline Brief Intervention + 2 Booster Sessions · Regression, Logistic · p = 0.6885 (significance threshold: p\<0.05) · Odds ratio (or): 1.202 · 95% CI 0.489 to 2.955text messaging vs. BI + 2 boosters.
  • General Information + SMS vs Baseline Brief Intervention + SMS · Regression, Logistic · p = 0.3483 (significance threshold: p\<0.05) · Odds ratio (or): 1.508 · 95% CI 0.639 to 3.555text messaging versus BI + text messaging
  • General Information + SMS vs Baseline Brief Intervention · Regression, Logistic · p = 0.7632 (significance threshold: p\<0.05) · Odds ratio (or): 0.865 · 95% CI 0.337 to 2.220text messaging versus BI
  • General Information vs Baseline Brief Intervention + 2 Booster Sessions · Regression, Logistic · p = 0.2972 (significance threshold: p\<0.05) · Odds ratio (or): 0.642 · 95% CI 0.279 to 1.477general information versus BI + 2 boosters
  • General Information vs Baseline Brief Intervention + SMS · Regression, Logistic · p = 0.5899 (significance threshold: p\<0.05) · Odds ratio (or): 0.805 · 95% CI 0.366 to 1.772general information versus BI + text messaging
  • Baseline Brief Intervention + 2 Booster Sessions vs Baseline Brief Intervention + 2 Booster Sessions + SMS · Regression, Logistic · p = 0.1153 (significance threshold: p\<0.05) · Odds ratio (or): 2.256 · 95% CI 0.820 to 6.212BI + 2 boosters + text messaging versus BI + 2 boosters
  • Baseline Brief Intervention vs Baseline Brief Intervention + 2 Booster Sessions + SMS · Regression, Logistic · p = 0.3656 (significance threshold: p\<0.05) · Odds ratio (or): 1.624 · 95% CI 0.568 to 4.644BI + 2 boosters + text messaging versus BI
  • Baseline Brief Intervention + SMS vs Baseline Brief Intervention + 2 Booster Sessions · Regression, Logistic · p = 0.5987 (significance threshold: p\<0.05) · Odds ratio (or): 1.254 · 95% CI 0.539 to 2.916BI + 2 boosters versus BI + text messaging
  • Baseline Brief Intervention vs Baseline Brief Intervention + 2 Booster Sessions · Regression, Logistic · p = 0.4877 (significance threshold: p\<0.05) · Odds ratio (or): 0.720 · 95% CI 0.284 to 1.822BI + 2 boosters versus BI
  • Baseline Brief Intervention vs Baseline Brief Intervention + SMS · Regression, Logistic · p = 0.2206 (significance threshold: p\<0.05) · Odds ratio (or): 0.574 · 95% CI 0.236 to 1.395BI + text messaging vs BI
SecondaryNumber of Participants With a Healthy Birth Outcome (Full-term Live Birth of Normal Birthweight, With no Days in NICU)

Healthy birth outcome, using birth outcome data from the state of birth, is defined as a full-term live birth (\>=36 weeks + 6 days) of normal birthweight (\>2500 gms) and with no days in neonatal intensive care.

Time frame:
Measured at birth, which was up to 42 weeks gestation
Reported as:
Count of participants · Participants
Number of Participants With a Healthy Birth Outcome (Full-term Live Birth of Normal Birthweight, With no Days in NICU)
ParticipantsGeneral InformationGeneral Information + SMSBaseline Brief InterventionBaseline Brief Intervention + SMSBaseline Brief Intervention + 2 Booster SessionsBaseline Brief Intervention + 2 Booster Sessions + SMS
Number of Participants With a Healthy Birth Outcome (Full-term Live Birth of Normal Birthweight, With no Days in NICU)474550544648
Statistical analysis
  • General Information vs General Information + SMS vs Baseline Brief Intervention vs Baseline Brief Intervention + SMS vs Baseline Brief Intervention + 2 Booster Sessions vs Baseline Brief Intervention + 2 Booster Sessions + SMS · Regression, Logistic · p = 0.439 (significance threshold: p\<0.05) · Odds ratio (or): 1.211 · 95% CI 0.567 to 2.588brief intervention versus no brief intervention
  • General Information vs General Information + SMS vs Baseline Brief Intervention vs Baseline Brief Intervention + SMS vs Baseline Brief Intervention + 2 Booster Sessions vs Baseline Brief Intervention + 2 Booster Sessions + SMS · Regression, Logistic · p = 0.5202 (significance threshold: p\<0.05) · Odds ratio (or): 1.373 · 95% CI 0.615 to 3.064brief intervention + 2 boosters versus no brief intervention
  • General Information vs General Information + SMS vs Baseline Brief Intervention vs Baseline Brief Intervention + SMS vs Baseline Brief Intervention + 2 Booster Sessions vs Baseline Brief Intervention + 2 Booster Sessions + SMS · Regression, Logistic · p = 0.7614 (significance threshold \<0.05) · Odds ratio (or): 1.134 · 95% CI 0.505 to 2.547brief intervention + 2 boosters versus brief intervention
  • General Information vs General Information + SMS vs Baseline Brief Intervention vs Baseline Brief Intervention + SMS vs Baseline Brief Intervention + 2 Booster Sessions vs Baseline Brief Intervention + 2 Booster Sessions + SMS · Regression, Logistic · p = 0.5202 (significance threshold: p\<0.05) · Odds ratio (or): 0.809 · 95% CI 0.424 to 1.543text messaging vs no text messaging

Adverse events

Collected over From enrollment (up to 20 weeks pregnant) until the end of follow-up (4 weeks postpartum), up to 44 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
General Information0/63 (0%)1/63 (1.6%)10/63 (15.9%)
General Information + SMS0/66 (0%)2/66 (3%)11/66 (16.7%)
Baseline Brief Intervention0/63 (0%)1/63 (1.6%)12/63 (19%)
Baseline Brief Intervention + SMS0/66 (0%)1/66 (1.5%)11/66 (16.7%)
Baseline Brief Intervention + 2 Booster Sessions0/63 (0%)4/63 (6.3%)23/63 (36.5%)
Baseline Brief Intervention + 2 Booster Sessions + SMS0/63 (0%)1/63 (1.6%)10/63 (15.9%)
Most frequent serious events
Most frequent serious events
EventGeneral InformationGeneral Information + SMSBaseline Brief InterventionBaseline Brief Intervention + SMSBaseline Brief Intervention + 2 Booster SessionsBaseline Brief Intervention + 2 Booster Sessions + SMS
Pregnancy LossPregnancy, puerperium and perinatal conditions1/632/661/631/662/631/63
Hospitalization (high blood pressure/preeclampsia)General disorders0/630/660/630/661/630/63
Hospitalization (vasa previa)Pregnancy, puerperium and perinatal conditions0/630/660/630/661/630/63
Most frequent other events
Most frequent other events
EventGeneral InformationGeneral Information + SMSBaseline Brief InterventionBaseline Brief Intervention + SMSBaseline Brief Intervention + 2 Booster SessionsBaseline Brief Intervention + 2 Booster Sessions + SMS
AnxietyGeneral disorders2/635/663/635/669/633/63
DepressionGeneral disorders2/631/665/634/669/634/63
Alcohol use (postpartum)General disorders2/633/664/630/665/633/63
HypertensionGeneral disorders4/632/660/632/660/630/63

Baseline characteristics

11 people were randomized but did not complete study intervention and assessments due to pregnancy loss (n=8) and participant withdrawal (n=3).

Age, Customized
Age, Customized(Participants)General InformationGeneral Information + SMSBaseline Brief InterventionBaseline Brief Intervention + SMSBaseline Brief Intervention + 2 Booster SessionsBaseline Brief Intervention + 2 Booster Sessions + SMSTotal
21 to 26 years old1412988556
27 to 29 years old15111512141481
30 to 32 years old181823261820123
33 to 35 years old152315191922113
Sex: Female, Male
Sex: Female, Male(Participants)General InformationGeneral Information + SMSBaseline Brief InterventionBaseline Brief Intervention + SMSBaseline Brief Intervention + 2 Booster SessionsBaseline Brief Intervention + 2 Booster Sessions + SMSTotal
Female626462655961373
Male0000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)General InformationGeneral Information + SMSBaseline Brief InterventionBaseline Brief Intervention + SMSBaseline Brief Intervention + 2 Booster SessionsBaseline Brief Intervention + 2 Booster Sessions + SMSTotal
American Indian or Alaska Native0001001
Asian0112239
Native Hawaiian or Other Pacific Islander0000000
Black or African American35751425
White555650555449319
More than one race41422316
Unknown or Not Reported0100023
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)General InformationGeneral Information + SMSBaseline Brief InterventionBaseline Brief Intervention + SMSBaseline Brief Intervention + 2 Booster SessionsBaseline Brief Intervention + 2 Booster Sessions + SMSTotal
Hispanic or Latino54135624
Not Hispanic or Latino576061625455349
Unknown or Not Reported0000000
08

Study locations

1 site
  • Michigan State University
    Flint, Michigan 48502, United States
09

References and documents

Publications

  • Ondersma SJ, Todd L, Jablonski S, Ahuja C, Gilstad-Hayden K, Goyert G, Loree A, Heffner J, Yonkers KA. Online randomised factorial trial of electronic Screening and Brief Intervention for alcohol use in pregnancy: a study protocol. BMJ Open. 2022 Aug 3;12(8):e062735. doi: 10.1136/bmjopen-2022-062735. PubMed 35922101 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data will be deposited in the National Institute on Alcohol Abuse and Alcoholism Data Archive (NIAAA DA). All collected Individual Participant Data (IPD) at the item level and individual subject level will be shared. The data will be identified only by Global Unique Identifier (GUID; no personally identifiable information will be shared).

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: In accordance with the Notice of NIAAA Data-Sharing Policy for Human Subjects Grants Research Funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) [2nd Revision], Notice Number NOT-AA-19-020, released July 31, 2019: Data will be shared with the general research community 2 years after the grant end date on the initial Notice of Award. However, if a manuscript using study data is accepted for publication prior to the 2-year embargo, the study data specifically used in that manuscript will be shared with the general research community at the time of publication. For this study, the grant end date is August 31, 2024, making the share date August 31, 2026 unless publication occurs prior to that date, in which case published data will be shared at the time of publication. The data are expected to remain available indefinitely unless sharing is limited by currently unforeseen circumstances.

Access criteria: Access to data for research purposes will be provided through the National Data Archive Data Access Committee (NDA DAC). Investigators and institutions seeking data from the NDA will be expected to meet data security measures and will be asked to submit a Data Use Certification, which is co-signed by the investigator and the designated Institutional Official(s) at the NIH-recognized sponsoring institution with a current Federal Wide Assurance (FWA). The procedures associated with data access are described at https://ndar.nih.gov/ndarpublicweb/policies.go#sop4

Data sharing details ↗ · ndar.nih.gov

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Aug 2025, 26 months.

Results were first posted in Oct 2026, 1 year 2 months after primary completion.

Of 28 interventional studies with no phase under Fetal Alcohol Spectrum Disorders, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 43. This study's 26 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2020
First posted
Apr 2, 2020
StartActual
May 19, 2023
Primary completionActual
Aug 6, 2025
CompletionActual
Aug 31, 2025
Results first posted
Oct 14, 2026
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 14, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedNumber of participants abstinent from alcoholParticipants Abstinent From Alcohol as measuredMeasured by Timeline FollowBack Calendar RecallTime frame: 90 days → 90 days prior to 34 weeks gestation
Oct 14, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedNumber of participants withParticipants With a healthy birth outcomeHealthy Birth Outcome (fullFull-term live birthLive Birth of normal birthweightNormal Birthweight, withWith no daysDays in NICU)Time frame: Entire period of gestation → Measured at birth, which was up to 42 weeks gestation
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedNumber of participants abstinent from alcoholParticipants Abstinent From Alcohol as measuredMeasured by Timeline FollowBack Calendar RecallTime frame: 90 days → 90 days prior to 34 weeks gestation
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedNumber of participants withParticipants With a healthy birth outcomeHealthy Birth Outcome (fullFull-term live birthLive Birth of normal birthweightNormal Birthweight, withWith no daysDays in NICU)Time frame: Entire period of gestation → Measured at birth, which was up to 42 weeks gestation
    + 3 other changes: verification date, arm descriptions and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04332172
Responsible party
Steven J. Ondersma (Professor and PI, Michigan State University) — Principal investigator
First posted
Apr 2, 2020
Start date
May 19, 2023
Primary completion
Aug 6, 2025
Completion
Aug 31, 2025
Results posted
Oct 14, 2026
Last update
Oct 14, 2026

Study contacts

Steven J Ondersma, PhD
principal investigator · Michigan State University
Kimberly A Yonkers, MD
principal investigator · UMass Chan Medical School

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion